Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting
October 21, 2019 10:30 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine
October 21, 2019 05:24 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
Targovax to present at upcoming investor and industry conferences
May 16, 2018 01:01 ET
|
Targovax ASA
Oslo, Norway, 16 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management...
Targovax ASA: First quarter 2018 results
May 03, 2018 01:03 ET
|
Targovax ASA
Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. ...
Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma
May 02, 2018 01:01 ET
|
Targovax ASA
Responses observed in three out of six patients Recruitment into the randomized part of the trial underway Oslo, Norway, 2 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused...
Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
April 25, 2018 08:18 ET
|
Targovax ASA
Reference is made to the annual general meeting of Targovax ASA (the "Company") on 11 April 2018 (the "AGM") where election of members to the board of directors was according to the nomination...
Targovax presentation at ChinaBio Partnering Forum 2018
April 25, 2018 01:01 ET
|
Targovax ASA
Oslo, Norway, 25 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumours, have today presented at the ChinaBio...
Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May
April 24, 2018 01:01 ET
|
Targovax ASA
Oslo, Norway, 24 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2018 results...
Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
April 12, 2018 08:48 ET
|
Targovax ASA
Oslo, Norway, 12 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the appointment of Catherine...
Targovax ASA: Protocol from the Annual General Meeting
April 11, 2018 04:42 ET
|
Targovax ASA
The annual general meeting was held on April 11, 2018 at the Company's offices at Lilleakerveien 2C, 0283 Oslo. Please find minutes of the meeting attached. For further information,...